Key Highlights GCTK shares skyrocketed approximately 118% during premarket hours, reaching $4.42 per share. The rally was triggered by Lōkahi Therapeutics securing its inaugural external fee-
Shares of GlucoTrack (GCTK) exploded approximately 118% during Thursday’s premarket session, climbing to $4.42. The dramatic price movement followed an announcement that Lōkahi Therapeutics, the company’s subsidiary, secured its first fee-for-service agreement with an external partner.
The partnership involves Innovate GBM, a charitable organization dedicated to glioblastoma brain cancer research. The nonprofit has retained two project teams from Lōkahi’s ai² PIPELINE division to conduct searches for brain tumor treatment candidates suitable for licensing and subsequent development.
This collaboration represents a significant achievement for Lōkahi, becoming the inaugural external entity to utilize the company’s proprietary asset discovery methodology, which leverages relationships with 14 academic institutions.
The premarket momentum positioned GlucoTrack among the session’s top performers, alongside companies such as Digital Currency X Technology and Greenland Mines.
The partnership announcement coincided with GlucoTrack providing shareholders with a comprehensive strategic overview. Chief Executive Officer Erik Emerson outlined the organization’s operational roadmap following the July 14 business combination transaction.
Glucotrack Technologies, the diabetes-focused division, maintains its status as a fully controlled subsidiary and continues advancing continuous glucose monitoring solutions.
Simultaneously, the parent organization is channeling capital resources and primary operational focus toward Lōkahi’s therapeutic asset discovery platform. This business model emphasizes acquiring clinical-stage pharmaceutical candidates at favorable valuations, advancing development with strategic discipline, and generating returns through licensing arrangements.
Currently, LT-100 represents the flagship development program—a biologic therapy designed to address osteoarthritis-related knee pain.
A revised clinical trial protocol is currently undergoing regulatory assessment. The proposed study will compare a once-weekly subcutaneous dosing schedule against the previous intradermal administration approach.
Company leadership indicated ongoing expansion of regulatory affairs, clinical operations infrastructure, and manufacturing capabilities to support LT-100’s progression through subsequent development milestones.
Emerson provided additional details regarding expansion plans for the ai² platform infrastructure. The Pipeline component evaluates thousands of discontinued late-stage pharmaceutical programs through established university and industry networks.
This evaluation methodology has already identified numerous promising candidates, with several advancing into preliminary business development discussions.
The platform architecture includes two additional components: ai² Talent and ai² Accelerator. These divisions focus on cultivating pharmaceutical industry expertise and supporting emerging ventures, including an initiative named Qare.
The overarching approach follows a cyclical pattern: asset identification, development advancement, followed by monetization. Leadership positioned this framework as generating diversified pathways for value creation.
Market analysts remain skeptical about the company’s current position. TipRanks’ AI-powered analyst, Spark, assigns GCTK an Underperform rating.
This assessment reflects challenging financial metrics, including zero revenue generation and substantial continuing losses. Cash consumption rates have also accelerated in recent periods.
Technical indicators compound the bearish outlook. Spark highlighted that share prices trade significantly beneath critical moving averages, accompanied by negative MACD momentum signals.
Valuation support remains constrained given persistent losses and absence of dividend distributions. Corporate developments were characterized as inconsistent, with enhanced funding flexibility counterbalanced by increasing shareholder dilution.
GlucoTrack maintains its listing on the Nasdaq exchange under ticker symbol GCTK. The stock records average daily volume of 767,577 shares, with a current market capitalization of $1.84 million.
The post GlucoTrack (GCTK) Stock Soars 118% on Lōkahi’s Debut Partnership Agreement appeared first on Blockonomi.
